What did @janiyahmichellee_ actually say?
The creator describes her personal experience using what she calls a "GLP-3" weight loss peptide she buys from an unregulated website for $60 per 10mg vial. She started at 2mg weekly, escalated to 4mg, then settled back at 2mg. She reports losing roughly 20 pounds in six weeks, with nausea and appetite suppression as her only side effects. She explicitly calls it a "gray market" purchase requiring needles sourced from Amazon, and she links to her vendor in her bio. She also claims the product is "99.9% purity" based solely on the vendor's word.
The drug she's almost certainly describing is retatrutide, a triple agonist (GIP, GLP-1, and glucagon receptors) currently in Phase 3 clinical trials by Eli Lilly. Calling it a "GLP-3" is inaccurate shorthand, but the mechanism and context make the identification fairly obvious.
Does the science back this up?
The weight loss claim is real, but the safety picture she paints is incomplete. Phase 2 trial data published in 2023 does support significant weight loss with retatrutide, but the trial used medically supervised dose escalation starting at 0.5mg, not 2mg.
Jastreboff et al. (2023, New England Journal of Medicine) found that retatrutide at higher doses produced up to 17.5% body weight reduction over 24 weeks in a controlled setting. The nausea she describes is consistent with GI adverse events reported in 45-65% of participants in that same trial. What she doesn't mention: the trial also recorded gallbladder-related events, elevated heart rate, and injection-site reactions at rates worth knowing about before you self-inject a research compound bought online. The appetite suppression she describes as a pleasant surprise is a known pharmacological effect, not a bonus feature.
What did they get wrong (or right)?
She got the subjective experience roughly right. Nausea in week one, appetite suppression that "sneaks up on you," and meaningful weight loss are all consistent with what the Phase 2 data shows. Credit where it's due.
What she got wrong is harder to overlook. First, she calls it a "GLP-3," which is not a real receptor class. Retatrutide is a GIP/GLP-1/glucagon triple agonist. Second, she started at 2mg when the Phase 2 protocol began at 0.5mg with slow escalation specifically because higher starting doses produced more severe GI events. Starting at 4x the recommended starting dose and calling yourself "perfectly fine" doesn't mean it was safe; it means you got lucky. Third, purity claims from an unregulated gray market vendor are unverifiable. No third-party certificate of analysis is mentioned. Bacterial contamination, incorrect peptide sequence, and inaccurate concentration are all documented risks in research peptide markets (Kaspar and Reichert, 2013, Drug Discovery Today).
What should you actually know?
Retatrutide is not approved by the FDA. It is a research compound. Buying it from a website and self-injecting without medical supervision carries real risks that a good six-week run doesn't erase.
The gray market peptide space has a contamination problem. A 2018 analysis by Erotokritou-Mulligan et al. found significant variability in peptide purity and concentration across unregulated suppliers. "99.9% purity" printed on a vendor website is a marketing claim, not a regulated guarantee. Beyond the product itself, dosing errors with injectable peptides can result in hypoglycemia, injection-site infection, or cardiovascular stress. The creator says she had no heart palpitations, but glucagon receptor agonism can elevate resting heart rate. That effect may not be immediately noticeable. If you are interested in peptide-based weight management, the conversation starts with a licensed provider who can run labs, review your history, and monitor your response. Not a TikTok bio link.
- Retatrutide is in Phase 3 trials as of 2024 and has no approved human dosing protocol outside of clinical research.
- Self-escalating to 4mg without medical oversight is not recommended by any published protocol.
- Nausea and appetite suppression are expected pharmacological effects, not unusual reactions.
- Gray market purity claims carry no regulatory weight.